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Introduction 
 
 
 
 
 
 
 
 
 
Bladder cancer is one of the most common urological malignancies. As per the Indian cancer 
registry data, it is the ninth most common cancer in men accounting for 3.9% of all cancer 
cases  (1). In the middle-aged and elderly men; bladder cancer is the second most prevalent 
malignancy after prostate cancer. It is well documented that the tobacco smoke and 
occupational carcinogens promote epithelial cell dysplasia and they are the most common 
environmental cause of urothelial carcinoma of the bladder. Most of these carcinogens are 
detoxified by phase II metabolic enzymes like Glutathione S transferase.  It is hypothesized 
that polymorphisms in genes encoding these enzymes, affects susceptibility to develop 
urothelial cancers (UC). One of the extensively studied genes in this group is glutathione S-
transferase P1 [GSTP1]. Studies of the relationship of polymorphisms of GSTP1 and UC of 
bladder have been equivocal, with some studies claiming positive associations with GSTP1 
polymorphism while the others claiming a negative association. This present study aims to 
assess the association between genetic polymorphism of GSTP1 gene and development of 
UC of bladder in patients presenting to Christian Medical College and Hospital, Vellore.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Aims and objectives 
 
 
 
 
 
 
 
 
 
 
Primary: 
• To detect any association of genetic polymorphism of glutathione S-transferase P1 
(GSTP1) gene with transitional cell carcinoma of the bladder 
 
Secondary 
• To assess if the risk of transitional cell carcinoma of the bladder is increased in 
smokers with polymorphism of GSTP1  gene polymorphism 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Review of Literature 
 
 
 
 
 
 
 
 
 
Epidemiology of bladder cancer: 
Carcinoma of the bladder is one of the most common urological malignancies. An estimated 
386,300 new cases and 150,200 deaths from bladder cancer occurred in 2008 worldwide (2) 
and then numbers are increasing due to the increase in the prevalence of smoking and 
environmental carcinogens. Smoking cessation programs appear to have reduced, but not 
completely negated this alarmingly rising incidence (3) The majority of bladder cancer 
occurs in males and there is a 14-fold variation in incidence internationally. It is four times 
more common in men compared with women. The mean age is approx 69 years in Men and 
71 years in females (4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Types of cancers of the bladder:  
There are various types of carcinoma bladder 
1. Transitional cell carcinoma(TCC) of the bladder or the urothelial carcinoma of the 
bladder 
2. Squamous(SCC) cell carcinoma of the bladder 
3. Adenocarcinoma of the bladder(5) 
4. Lymphoma of the bladder 
5. Sarcoma of the bladder(6) 
 
TCC or urothelial carcinoma of the bladder is the most common type of the cancer of the 
bladder, accounting for approximately 90% of the cancers of the urinary bladder 
 
Classification 
TCC of the bladder is broadly classified into two types: 
1. Non muscle invasive carcinoma of the bladder 
2. Muscle invasive carcinoma 
Based upon the histological grading, it is divided into: 
1. Low grade 
2. High grade carcinoma of the bladder. 
 
The WHO recommends(7) the use of the term ‘urothelial cancer’ (8) as opposed to the more 
widespread ‘transitional cell carcinoma’. The current classification of grade is widely 
accepted by both urologists and pathologists. Malignant neoplasms are classified as low-
grade and high-grade (7) depending on the nuclear and cellular architecture. It is the grade, 
not stage that is the most important predictor of progression. The low-grade and high-grade 
tumours can be regarded as distinct diseases with respect to tumour biology, their genetic 
origin and ultimately management.  
 
 
 
Figure 1: Stages of urothelial carcinoma 
The figure 1 diagrammatically depicts the various stage of the urothelial carcinoma of the 
bladder.  
Ta tumours are the ones confined to the epithelial layers and they are usually slow growing 
and non muscle invasive i.e. basement membrane is not invaded. Their peculiar 
characteristic is that they may recur many times before they progress to muscle invasive 
disease  or become metastatic (9).   
 
Carcinoma in situ or CIS represents a different entity. Here, there is no papillary tumour but 
occurs severe dysplasia at the cellular level. If CIS is found next to the area where low grade 
tumour is present, it behaves more aggressively and there is higher chances of muscle 
invasion in the future. (10) There have been studies from different centers treating CIS by 
early radical cystectomy with a definite survival benefit as compared to patients who were 
managed with repeated transurethral resections (11). Invasive bladder cancer occurs in 
more than 75 % of these patients. (12) 
 
T1 tumours involve the lamina propria and the muscle is free. Their treatment varies if they 
are low grade or high grade, as the low grade tumour usually behave indolent while the high 
grade T1 tumours are more aggressive and recurrent, requiring aggressive management. 
These have much higher chances of recurrence as well as progression. (13) Since these have 
higher propensity of progression and recurrence, these are often initially treated with 
immunotherapy, mainly BCG(14) 
 
T2 tumours involve the detrusor muscle and are usually treated by radical cystectomy, with 
or without adjuvant therapy (7). Long term cancer free results can be available if radical 
cystectomy is done at a stage when it is amenable to cure.(15) 
 
T3 tumours extend beyond the bladder i.e. extravesical disease. (16). Various targeted 
therapies are available to downstage the disease before radical cystectomy  (17).  
 
T4 tumours invade the adjacent organs like prostate, seminal vesicles, pelvic bones etc. The 
survival of these patients is uniformly poor. Even after the availability of various 
chemotherapy regimens, the survival has not improved much.  Efforts have been made to 
look upon various biochemical pathways and identify genetic lesions so that in future the 
disease is arrested in the earlier stages or better modalities are offered (18). 
 
Bladder cancer or the urothelial cancer is called a multifocal disease due to the theory of 
field cancerization i.e. the tumour tends to recur at the sites away from the original site 
where it was present earlier. But the genetic studies give a contrary view of its being of 
monoclonal origin. Simon et al studied 32 tumours from cystectomy specimens and found 
17p losses in all tumours along with a very high numbers of chromosomal changes. They 
also found an identical TP53 mutation in all the tumours as well as the adjoining normal 
looking mucosa. They hypothesized that the tumour cells carry a specific chromosomal 
aberrations at the intraepithelial level thus suggesting a monoclonal origin of the multifocal 
bladder tumour  (19). 
Most of the carcinogens in the body are detoxified and excreted in the urine and hence the 
urothelium is exposed to various carcinogens. This explains the multifocal occurrence of the 
various urothelial tumors in the upper urinary tract and the bladder. 
 
Etiology and the risk factors for TCC bladder (20): Environmental risk factors and genetic 
factors 
1. Smoking, both active and passive smoking. 
2. Occupational carcinogens 
3. Genetic effects 
 
Smoking: Smoking is an established risk factor for transitional cell carcinoma of the bladder.  
For active smokers, the risk is approx 4 times as compared to non-smokers. If a person stops 
smoking, though the risk decreases gradually, it doesn’t touch the baseline even after 20 
years.(21) 
Even passive smoking is associated with increased risk of TCC bladder and other cancers.(22) 
Urothelial tumours in smokers are usually of higher grade and they have worse 
prognosis.(23) Apart from these, smoking also decreases the general health of the patient 
and it is one of the commonest factor which delays the curative surgical management of the 
cancer patients. The trend towards smoking is increasing in the urban and the younger 
population. 
Occupational carcinogens:  Metal workers, rubber industry workers, leather workers, 
miners, cement workers, painters, plastic and other industrial workers. Bladder cancer also 
has been associated with exposure polycyclic aromatic hydrocarbons (PAHs), paint 
components, and diesel exhausts. (24) 
Miscellaneous risk factors known to cause TCC of the bladder are chronic cystitis, HPV 
infection(25), bladder augmentation, neurogenic bladder (26), upper urinary tract cancers, 
radiation to the pelvis, chronic analgesics and cyclophosphamide chemotherapy. 
Genetic effects: 
TCC has long been known to cluster in families suggesting a role for genetic factors. Studies 
by Aben et al and Goldar et al have shown increased risk of TCC bladder in the relatives of 
the patients with TCC (27,28). In literature there are reports of two successive generations 
being affected suggesting an autosomal dominant pattern (29) How ever though Mendelian 
pattern of inheritance has been spoken about, contrary to the belief second and third 
degree relatives had higher observed to expected ratio of TCC than first degree relatives yet 
again suggesting other modes of inheritance. As per large scale studies inheritance clearly 
appears to be multifactorial.   The risk was more in relatives who were smokers than in non 
smokers. These patients also have bladder cancer at a much younger age than with no 
family history of TCC bladder; however some studies have not found the same.  
Complex interactions of susceptibility genes, environmental risk factors leading to activation 
of Oncogenes and suppression of tumour suppressor genes leading to carcinogenesis in the 
urothelium has been suggested. 
 
Susceptibility for bladder cancer has been studied using Genome Wide Association Studies 
[GWAS], which suggested an association with genes like TACC3 (30)  as well showing some 
association with few SNPs upstream of MYC gene and TP53 (31). The natural history of the 
TCC bladder can get altered due to the complex interactions of these factors. 
 
 It has been also suggested that genetic factors increase the risk of TCC bladder by altering 
the ability to detoxify carcinogen precursors however GWAS did not show any hits in the 
genomic regions having genes for the xenobiotic enzymes.  
 
Pathogenesis: 
As described above, the strong association of TCC with tobacco smoking is due to various 
carcinogens in the tobacco smoke. Cigarette might look harmless in a white classic paper, 
but when it burnt releases many harmful chemicals, which can cause cancers of the various 
parts of the body 
Cancer causing agents in cigarette smoke are(32): Tar, arsenic, cadmium, formaldehyde, 
benzene, polycyclic aromatic compounds, nitrosamines, Acrolein, cadmium, carbon 
monoxide, ammonia and many others.  
Most of the above mentioned carcinogens, apart from heavy metals are detoxified by series 
of xenobiotic enzymes. The xenobiotic metabolizing enzymes are divided historically into 
phase I enzymes, which are exclusively cytochrome P-450 dependent and phase II enzymes, 
such as Glutathione transferase (GST) and sulpho-transferase. These carcinogens are mainly 
detoxified by phase II metabolic enzymes like Glutathione S transferase (33,34). These are 
involved in N-oxidation to N-hydroxylation metabolites.   
 
These enzymes are polymorphic i.e. there are variants with slightly different molecular 
structures and hence differential biologic activities. There are many Case-control studies 
suggesting that cigarette smokers with different polymorphisms have a differential risk for 
bladder cancer.(35) 
Various studies have looked at GSTP and GSTM polymorphisms and their association with 
TCC bladder. The results of studies have been conflicting, though majority of studies have 
found significant associations with particular polymorphisms (36). It is generally accepted 
that overall GST activity is also up regulated in transitional cell carcinoma (TCC) of the 
urinary bladder and GSTP1 accounts for the majority of this increase(37). 
The polymorphisms mentioned above, lead to over excretion of the aromatic amines and 
polycyclic hydrocarbons, causing oxidative damage to the DNA of the bladder epithelium 
there by leading to urothelial carcinoma of the bladder (38).The DNA damage leads to 
activation of oncogenes and suppression of tumor suppressor genes resulting in 
unregulated clonal proliferation. The same has been examined in few studies. Role of TP53 
has also been studied; it is a cell cycle regulator, a meta-analysis of 168 studies done by 
Malat et al showed a significant association of p53 over expression in TCC bladder (39). 
Approximately 50% of the bladder tumour has somatic mutations in the TP53 gene (40–42). 
Retinoblastoma gene is also involved in controlling the cell division process. Alteration in 
this gene is also associated with TCC bladder.(43) 
 
 
Figure 2: Hypothetical diagram of a gene 
 
 
The gene (Fig 2) was defined classically as a segment of DNA encoding a protein (44). 
Various genes are present in the double helix DNA. In a particular gene, two regions are 
present called Introns and the Exons. When the DNA is transcribed into RNA, the introns are 
the regions which are removed in the splicing process while the remaining Exons encode the 
protein. The DNA replication is a highly accurate process but rarely errors in DNA replication 
can occur, causing spontaneous alteration in the base sequence of the particular gene. 
These errors are called mutations and they do affect the phenotype occasionally. 
 Genotype: The combination of two alleles at one genomic location and/or base pair in an 
individual 
 
Polymorphism: in simple words, it is the occurrence of more than one form or morph. 
Genetic polymorphism is defined as a variant of alternative DNA sequence or chromosome 
copy number that can be found in a population. 
Genetic polymorphism: definition as given by Phillip Hedrick, is the occurrence in the same 
population of two or more alleles at one locus, each with appreciable frequency", where the 
minimum frequency is typically taken as 1%. (45) It is hypothesized that the polymorphism 
might alter a particular enzyme’s function and makes it weaker or more potent.  
 
 
GLUTATHIONE S TRANSFERASE 
Structure and types of GST 
The complete human genomic glutathione-S-transferase-pi gene (GST-pi) was isolated from 
a lambda Charon 4A bacteriophage library which was screened by hybridization to a human 
GST-pi cDNA. The GST-pi gene has 7 exons and 6 introns contained within approximately 2.8 
kilo-bases.(46) 
 
The mammalian GST enzyme superfamily consists of cytosolic dimeric isoenzymes of size 45-
55KDa. Till date, human cytosolic GST enzymes are subdivided into 8 subtypes: alpha, mu, 
kappa, omega, pi, sigma, theta and zeta. This classification is based on immunological cross-
reactivity and on the basis of sequence similarity. The structure and the mechanism of 
glutathione-S-transferase are studied by site directed mutagenesis and X-ray crystallography 
(47). These subtypes are encoded by the genes GSTA, GSTM, GSTK, GSTO, GSTP, GSTS, GSTT 
and GSTZ, respectively. But among these, the functional polymorphism is only indentified in 
the GSTM1, GSTP1 and GSTT1 gene (46,48). 
GSTP1 is the most commonly studied enzyme amongst all these. It is located on 
chromosome 11q13. It is well recognised and is proved in various studies that GSTP1 plays 
an important role in protecting cells from various carcinogenic as well as from cytotoxic 
agents. It is well expressed in different cell types, as described above. GSTP1 DNA 
hypermethylation at the CpG island in the promoter-5’ region can result in the altered or 
decreased GSTP1 activity (49). 
 
Functions of Glutathione S Transferase 
GST enzymes are the major phase II detoxifation enzymes found mainly in the cytosol in 
mammals (50). It catalyses the conjugation of the reduced glutathione (GSH) with the 
compounds that contain an electrophilic centre through the formation of the thioester bond 
between the sulphur atom of GSH and the substrate(51). Other than conjugation reactions, 
GST enzymes also have non-catalytic functions like intracellular transport of hydrophobic 
ligands, segregation of carcinogens and modulation of signal transduction pathways.(52) 
 
Below mentioned (Figure 3) is the hypothetical natent structure of the GSTP1 protein and if 
at 313 position of DNA, there is a change of nucleotide Adenosine to Guanine, the isoleucine 
at 105th position of the protein changes to valine and it has been suggested that this leads to 
structural alteration in the protein causing diminished enzymatic activity. The introduction 
of valine is hypothesized to alter the protein to such a level that it responds less to the 
toxins in the body and thus predisposes the individual to develop cancer. 
 
 
Figure 3: Figure depicting the hypothetical natent structure of GSTP1 protein and the 
changes occurring which causes the protein to have diminished activity.  
This substitution leads to three GSTP1 genotypes: Homozygous wild type isoleucine/ 
isoleucine allele (ile/ile), heterozygous isoleucine /valine allele (ile/val) and homozygous 
polymorphic valine/valine allele (val/val) 
 
Various biochemical studies indicate that GSTP1 polymorphic valine allele has a lower 
thermal stability than GSTP1 homozygous isoleucine wild allele. The valine allele has a lower 
conjugating activity and the heterozygous isoleucine/ valine allele has an intermediate 
thermal stability.  
 
Table 1: Normal tissue distribution of GSTP1 
 
Super family Class Chromosome Protein Organs 
Soluble Pi 11q13 GSTP1 Brain>heart=lung=testis>kidney=pancreas 
 
The table 1 depicts the normal distribution of GSTP1 protein in the body. Pi class of 
glutathione-S-transferase is located on chromosome 11q13 (53). It is expressed in normal 
tissues at variable concentration in the body with the maximum amount in the brain and in 
the heart, lungs, testis, kidneys and the pancreas In the decreasing order respectively. 
Although there are various polymorphism described in GST genes, the physicochemical 
approaches to detect polymorphism were limited to analysis of three Classes Alpha, Mu and 
Pi isoenzymes.  
 
 
 
 
 
 
 
Table 2: Polymorphic GSTP1 
Class Gene Allele Alteration in gene or in 
nucleotide 
Protein or amino acid affected 
Pi GSTP1 GSTP1 A A313,C341,C555 Ile 105, Ala 114, Ser 185 
  GSTP1 B G313,C341,T555 Val 105, Ala 114, Ser 185 
  GSTP1 C G313.T341,T555 Val 105, Val 114, Ser 185 
  GSTP1 D A313,T341 Ile 105, Val 114 
 
Four different GSTP1 allele have been identified according to the SNPs at different positions 
in the open reading frame of GSTP1 gene leading to the substitution of amino-acids at 105 
and 114 as illustrated in the table above (Table 2).  These polymorphisms make significant 
inter-individual difference in the drug or toxin metabolism. But polymorphism in individual 
genes does not obviously confer a markedly increase in risk of the cancer. In various studies, 
typically odds ratio associated with any single variant GST allele and the development of 
particular neoplastic disease are found to be less than 3.0(54) 
 
The GST polymorphism not only appears to influence susceptibility to disease and but also 
influences the responsiveness to various carcinogens.  Apart from urothelial cancers, GST 
polymorphism has been implicated in various cancers like hepatocellular carcinoma, breast 
cancer, prostate cancer, renal cancers, testicular cancers etc.(55) 
Various studies imply that even with occupational exposure, GSTP1 polymorphism is 
associated with increased risk of DNA damage. (56) 
 
 
Methods involved for studying polymorphism in genes 
1. DNA extraction 
2. Polymerase chain reactions 
3. Restriction fragment length polymorphism 
4. Gel casting 
5. Electrophoresis 
 
DNA extraction or Isolation:  
DNA extraction is the process of purifying DNA from sample. It involves both physical 
methods and chemical methods. It was first described by Friedrich Miescher in 1869. It is a 
routine method used in molecular biology or forensic analyses. 
 
Basic procedure of DNA extraction:  
The following steps are used for DNA extraction: 
The cells consist of biomolecules namely nucleic acids, proteins, carbohydrates and lipids.  
Other molecules have to be removed to isolate the nucleic acid. 
First step is to lyse the RBCs using the RBC Lysis buffer. The remaining lysate consists of 
WBCs which are disrupted using cell lysis solution – a detergent (SDS). The cellular and 
histone proteins which are bound to DNA are denatured and precipitated using protein 
precipitation solution (Proteinase K an enzyme).  This precipitated solution is treated with 
Phenol-chloroform to lyse the carbohydrates and lipids which then along with the lysed 
protein separate into aqueous phase and organic phase, the DNA suspended in the aqueous 
phase. Suspended nucleic acid is precipitated using 100% ethanol. The remaining salts are 
removed by washing the nucleic acid with 70% ethanol twice or thrice. The DNA is allowed 
to dry and is resuspended in Tris-EDTA buffer (TE).  
TE buffer comprises of Tris buffer and EDTA that chelates magnesium ions. TE buffer 
prevents DNA degradation. 
Polymerase chain reaction (PCR): PCR was developed by Kary Mullis in 1983. It is the 
technique which involves enzymatic exponential amplification of DNA generating thousands 
to millions of copies of the target DNA sequence. 
PCR Method depends upon thermal cycling (Peltier effect) i.e. repeated cycles of heating 
and cooling of DNA to attain the required temperature for the successful DNA amplification. 
The two key components involved are the short single stranded oligonucleotides (DNA 
fragments 18nt to 20nt in length) or the primers which are complementary to the target 
DNA sequence and a proof reading Taq DNA polymerase enzyme which catalyses the 
enzymatic amplification. As the reaction continues, DNA gets amplified in an exponential 
pattern and the product obtained at the end of each cycle acts as the template for the next 
cycle.  
 
Steps of PCR 
1. DNA template containing the specific DNA region to be amplified. 
2. Forward and reverse primers complementary to the sense and anti-sense strand of 
the DNA target. 
3. Taq DNA polymerase with a temperature optimum at 72 °C. 
4. dNTPs (deoxynucleotide triphosphates - building-blocks) which the DNA polymerase 
utilizes to synthesis a new DNA strand. 
5. A Buffer solution to maintain proper chemical environment for optimal enzymatic 
activity and to stabilize DNA polymerase 
6. Divalent cations (magnesium ions) acts as a cofactor to the DNA polymerase 
7. Monovalent cation potassium ions are used for DNA stabilization. 
Small reaction tubes of 0.2-0.5 ml are used to carry out PCR. These tubes are kept in a 
thermal cycler, which alternatively heats and cools the reaction tubes to achieve the desired 
temperature. 
 
Procedure of PCR: PCR consists of approximately of 20-40 repeated temperature cycles in 
the thermal cycler 
1. Denaturation step: In this step the genomic DNA double helix are physically 
separated into two strands. This involves heating the sample at 94–98 °C for 5min. 
Longer duration is given to achieve complete denaturation of the genomic DNA. At 
high temperature the H bonds between the nucleotides break and the DNA attains 
single stranded conformation. However subsequent denaturation steps are done for 
lesser duration (1 min) since this time the target region has to be separated into 
single stranded. 
2. Annealing step: During this step the primers get annealed to their complementary 
sequences in the target region. The optimal annealing temperature is 50–65 °C for 
20–40 seconds. The primers form H bonds with their complementary nucleotide. The 
Taq polymerase binds to the primer-template complex which is now ready for 
extension of the target region. 
3. Extension/elongation step: The extension temperature depends on the type of DNA 
polymerase. Taq DNA polymerase required 72°C for extension. The time required for 
extension depends on the length of target region. The optimal time is 1 min for 
extension of 1000bp target length. DNA polymerase utilizes the dNTP which are 
added to the 3 prime end of the primer and the fragment is extended.  
4. Final elongation: This is performed at a temperature of 72 °C for 5–15 minutes after 
the last cycle of PCR. This ensures that all the end fragments are completely 
extended. 
5. Final hold: This step is applied for short-term storage of the reaction  for an 
indefinite time 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Schematic drawing of the PCR cycle. 
 
 
Restriction fragment length polymorphism 
In RFLP analysis, the DNA fragment is restricted (digested) by restriction enzymes 
(endonucleases) and the fragments thus obtained are separated according to their 
respective lengths (base pairs) by gel electrophoresis 
 
 
Restriction enzyme: 
The PCR product is digested with the restriction enzyme called Alw26I. It is a fast digest 
enzyme for rapid DNA digestion. It recognizes and cleaves the DNA wherever a specific short 
sequence (usually palindromic) occurs. The Alw26I restriction enzyme recognizes 5’GTCTC3’ 
sites and cuts best at 37°C overnight. Fast digestion is done at 56°C for 1 hour. 
RECOGNITION SITE: 
5’    G   T   C   T   C   N    N   N   N   N    3’ 
3’    C   A   G   A   G   N   N   N   N   N    5’ 
 
Gel electrophoresis: Based upon the size and the charge, DNA or RNA is separated for 
analysis using an electric field by a method called electrophoresis. They can be made to 
migrate through the pores of an Agarose gel or polyacrylamide gel. After connecting to the 
power source (120V and 400mA) the gel is placed in an electrophoresis chamber. Now the 
electric field is applied to move the negatively charged DNA molecules through the agarose 
matrix from cathode to anode. 
DNA is loaded in wells of the gel and molecules migrate through the matrix at different 
rates. The smaller fragments migrate easily through the pores of the gel compared to the 
longer or larger fragments. Hence different sized DNA fragments are seen as distinct bands 
which can be easily read. Often many numbers of samples are loaded simultaneously in the 
adjacent wells. Hence fragments of similar weight move together, parallel in their individual 
lanes and will be at a uniform distance from the wells. 
 Types of the Gel 
1. Agarose 
2. Polyacrylamide 
3. Starch 
Agarose gel: Although they do not have uniform pores, they are optimal for electrophoresis 
of DNA. The percentage of the agarose in the gel determines the distance travelled by 
different molecules of the DNA. Larger fragments of DNA are separated in lower percentage 
of agarose to facilitate the movement of DNA through small pores and smaller sized 
fragments are separated in higher percentage of agarose. The agarose gel is easy to made, 
stable and can be handled easily as compared to other gels. The remaining gel can be stored 
easily in the refrigerator, to be used again. In case the gel is of high percentage of agarose, 
the use of pulsed field electrophoresis or field inversion electrophoresis can be used to 
hasten up the speed of electrophoresis. These gel are often brittle and do not set easily. Low 
percentage gel is very weak and breaks when lifted. 1% agarose gel is often used commonly 
in genetic studies. 
Buffers: Ions in the buffer carry current and facilitate the DNA movement from cathode to 
anode. They also maintain constant pH. Most commonly used buffers are Tris Acetate EDTA 
(TAE) and Tris Borate EDTA (TBE) 
Visualization: The molecules in the gel are fluorescently stained to make them visible under 
UV after the electrophoresis. Ethidium bromide is used for fluorescently staining DNA. 
Ethidium bromide is carcinogenic; care is required to handle it. Ethidium bromide 
intercalates into DNA and is perpendicular to the axis. It emits radiation energy at 590nm 
under ultraviolet light. This makes the visualization very clear. Gel documentation Unit takes 
the photographs which are then studied for final results. Shown below (figure 5) is the gel 
electrophoresis picture. 
Figure 5: Gel electrophoresis picture 
 
 
Various studies have shown that glutathione S transferase is not only involved in urothelial 
cancers, but also in the renal cancer and the cancers of the prostate (55). In the presence of 
risk factors, although the prevalence of Urothelial carcinoma of bladder is higher, not all 
exposed individuals are affected with cancer. Thus it is hypothesized that polymorphism in 
the group of genes, resulting in decrease in the level of GST enzyme, may lead to increase 
risk of urothelial cancers. 
Since the discovery of the potential association of GSTT1 and bladder cancer in 1996, 
various studies have investigated the association between TCC bladder and GSTs genes. 
Many studies have seen the relationship of TCC bladder with the polymorphism of GSTP1 
gene along with GSTM1 and GSTT1 polymorphism reported that in Turkish population (57), 
GSTP1313 A/G or G/G genotype increases the susceptibility of urothelial cancer by 1.75 
times. Srivastava et al (58) in the north Indian population 2005 reported a strong association 
of homozygous polymorphic valine allele and urothelial cancer of the bladder. They 
reported more than 7 times increased association with GSTP1 polymorphism and urothelial 
cancer of the bladder. He also proved that if the three genotypes of GST are combined, the 
gene-gene interaction further increases the risk of urothelial cancer of the bladder. 
Safarinejad MR et al in 2011 suggested that polymorphism of GSTP1 along with GSTM1, and 
GSTT1 may be associated with increased bladder cancer risk in the Iranian population(34) 
Ercegovac MP et al in 2008 concluded that along with increased GSTP1 over expression in 
transitional cell carcinoma patients, altered apoptotic pathway was also seen.(59) 
 
But Goerlitz D et al in 2011 did not find any association of TCC bladder with GSTP1 
polymorphism. They suggested no association with Genotypes and smoking, environmental 
toxins or infection.(60) 
 
Similar observations were seen by Katoh T et al(61) in Japanese population, they found no 
association of between valine polymorphism in control or cancer population. They also 
found no association of polymorphism between smokers and never smokers in any of the 
cancer group, oral, lung, gastric or urothelial cancers 
Steinhoff C et al in German population(62) also suggested no correlation between GSTP1 
polymorphism and Urothelial carcinoma of the bladder. Pandith AA et al(63)  also found no 
statistical significance difference in the genotype frequencies between the cancer and the 
control population in Kashmir Indian population. They also found a significant risk of more 
than 2.5 times for the polymorphic allele (AG+GG) with smokers in cases as compared to 
controls (p<0.05)  
Hence the results in these epidemiologic studies in literature were very inconsistent and 
conflicting with some studies showing increased risks and the other showing no association 
with bladder cancer and GSTP1 polymorphism 
 
 
The purpose of our study was to determine the frequencies of polymorphisms of GSTP1 
genes and their association with TCC bladder among the patients presenting to a tertiary 
care urology centre. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Material and methods 
 
 
 
 
 
 
 
This was a prospective study done at the Department of Urology and Medical Genetics of a 
tertiary care hospital, for a period of one year from August 2012 to July 2013. It was approved 
by the institutional review board, (Institutional research board no: 8063/6.11.2012). 
Subjects- Cases and Controls 
This study consisted of total 98 patients, 52 patients with histo-pathologically confirmed 
diagnosis of Primary TCC bladder (mean age ± SD, 56.2 ± 10.6) and 46 cancer free controls 
who presented with non-malignant urological problems (Mean age: 52.7± 13.2)  
 
Criteria for the patient selection were based on a questionnaire covering medical, 
pathological, and histo-pathological records in Christian Medical College and Hospital (CMC) 
Vellore.  All patients were carefully paired with controls to avoid any bias or confounding 
factors. They were selected in regards to Age, smoking or tobacco chewing habits, 
occupational exposure, diet factors, family history of cancers and smoking awareness. Since 
CMC caters to a wide variety of patients from different ethnic origin, both the cases and 
controls were carefully matched for their ethnic origin. No patient had a prior history of 
chemotherapy or radiotherapy before recruitment because it is a well known that 
chemotherapy and radiotherapy can cause damage to the DNA, resulting in false and 
misleading results. Majority of the controls were the patients undergoing treatment for 
urethral stricture disease or the renal/ ureteric stones and they underwent cystoscopy to 
rule out obvious urothelial carcinoma of the bladder. 
Informed consent was taken from all the subjects before they participated into this study. 
This was conducted according to Helsinki declaration (2004). 
 
 Inclusion /Exclusion criteria:  Case group were the patients with the diagnosis of Primary 
TCC bladder. All patients who had metastasis to bladder or with previous history of 
radiotherapy or chemotherapy were excluded. 
In the control groups, we took patients with non-malignant urological diseases and without 
history of any other malignancy in the past and in cystoscopy, no evidence of TCC was seen. 
  
Evaluation: All subjects were asked relevant history and they had a complete physical 
examination and answered a structured proforma that included demographic background, 
smoking awareness and smoking habits, occupational history, Chronic disabling illness, 
personal and medical history. 
We considered the subject as a non-smoker, if he has not smoked for the last 10 years. Only 
the subjects with the biopsy proven TCC bladder were taken, either after the transurethral 
resection of the bladder tumor or after the radical cystectomy. The tumors were classified 
as Non-muscle invasive Bladder (pTa–pT1) or muscle invasive (pT2–pT4) according to the 
TNM staging system of the American Joint Committee on Cancer. 
 
 
 
 
 
 
 
 
 Table 3: TNM staging of the Transitional cell carcinoma of the bladder 
 
Ta Papillary, epithelium confined 
Tis Flat carcinoma in situ 
T1 Lamina propria invasion 
T2a Superficial muscularis propria invasion 
T2b Deep muscularis propria invasion 
T3a Microscopic extension into perivesical fat 
T3b Macroscopic extension into perivesical fat 
T4a Cancer invading pelvic viscera (e.g., prostatic stroma, vaginal wall, rectum, uterus) 
T4b Extension to pelvic sidewalls, abdominal walls, or bony pelvis 
N0 No histologic pelvic node metastases 
N1 Single positive node ≤2 cm in diameter, below common iliacs 
N2 Single positive node 2-5 cm in greatest diameter or multiple positive nodes 
N3 Positive nodes >5 cm in diameter 
Nx Nodal status unknown 
M0 No distant metastases 
M1 Distant metastases documented 
Mx Distant metastases status uncertain 
  The histological grades were subdivided into low grade and high grade according to the 
WHO classification (WHO) and the International Society of Urological Pathology (ISUP) 
 
Genotyping and Method of estimation: The GSTP1 genotype was determined by PCR-
restriction fragment length polymorphism (RFLP) technique. 
For the extraction of genomic DNA from the blood sample, the RBC are lysed and DNA 
extracted from the WBC. They are centrifuged and pellets are made. As shown in the figure 
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Figure 6: Centrifugation of the serum 
 
 
  
Figure 7: Amplification is done in the PCR machine: 
 
 
 
Using the primer pair, a 177 bp fragment of the GSTP1 gene containing Ile to Val 
substitution in exon 5 (codon 105) will be amplified (Figure 7) 
Forward: 5'-ACC CCA GGG CTC TAT GGG AA-3' and 
 Reverse: 5'-TGA GGG CAC AAG AAG CCC CT-3'.     
The amplification cycles included an initial denaturing at 94°C for 30 seconds, followed by an 
annealing step at 55°C for 30 seconds, and a final extension step at 72°C for 30 seconds, a 
slight modification from the method described by Safarinejad MR et el. The PCR products 
then will be digested with Alw26I restriction enzyme.  
Figure 8: Gel electrophoresis picture 
 
 
Dye is added to the Restriction products and they are analyzed by 2% agarose gel.  
The PCR product (Figure 9):  
 
 
Homozygous Ile/Ile individuals will have a single fragment of 177-bp (base-pairs) and it 
appears as a dark band, and homozygous Val/Val individuals will have both 92- and 85-bp 
fragments- appearing as a faded band. The presence of all 3 fragments will correspond to 
heterozygous Ile/Val individuals. 
 
FLOW CHART 
Collection of EDTA Blood Samples 
 
Extraction of DNA 
 
Amplification of 177 bp fragment of exon 5 of GSTP1 
 
Digestion of the PCR products with Restriction Enzyme 
 
Gel casting and analysis 
 
 
 
Quality control: To maintain a good quality control, 10 % of the duplicates for both the 
cases and the controls were genotyped with 100% concordance to the genotype by PCR-
RFLP 
Even the laboratory personnel were not able to differentiate between the cases and control 
samples. 
 
Statistical methods: The power of the study – 80% was determined considering of following 
variables:  
1. Case-control study design 
2. Significance level 5 % (2 sided) 
3. Expected frequency of risk allele in the control population = 0.28 
4. The genetic effect for odds ratio (OR) 2.5 or greater. 
 
Assuming log-additive model of inheritance and frequency of risk allele to be 0.28 [-ref], a 
total sample size of 98 (52 cases/ 46 controls) would be required to detect an odds ratio of 
2.5 or more with a desired power of 80% and a significance level of 5%  
Results are expressed as mean ± standard deviation (SD).  
 
Hardy-Weinberg equilibrium was examined using the goodness-of-fit X2 test. It is done to 
compare the observed allele frequencies in the study with the expected frequencies 
determined from control subjects.  
To assess the homogeneity between cases and controls regarding their geographic origin, 
smoking awareness, cigarette smoking, disease pathological status and genotypes, the X2 or 
Fisher’s (F) exact test was used. 
To determine the association of polymorphisms with susceptibility to develop TCC and 
between the various clinicopathological characteristics of bladder cancer, we used 
unconditional logistic regression to estimate adjusted odds ratios and 95% confidence 
intervals (CI). Statistical Package for the Social Sciences (SPSS 18) was used for statistical 
analysis. 
 
Figure 9: Representative PCR-RFLP products  
 
 
Restriction-digestion of The PCR products of GSTP1 gene by the Alw26I restriction 
endonuclease.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Results 
 
 
 
 
 
 
 
 
 
 
 
Characteristics of the study population 
Table 4 shows the demographic and clinical characteristics of both the cases and the 
controls  
 Both the groups are matched on the basis of Age, gender and geographic distribution. 
There was no confounding factor seen. 
Table 4 
Demographic characteristics of the cases and controls 
Characteristics  Cases (n-52) Controls(n-46) P values 
Age(yrs) 56.2± 10.6 52.7± 13.2 0.151 
Gender Male 45 40  
0.950 Female 7 6 
Origin North 11 7  
0.511 North-East 30 25 
South 11 14 
Smoker Yes 32 12  
No 20 34 
Awareness- smoking 
causes bladder cancer 
Yes 30 44 
No 20 2 
Occupational  exposure Yes 19 8 
 
As shown in the table 4, the mean age of the cases were 56.2± 10.6 years and the mean age 
of the controls were 52.7± 13.2 years (p value- 0.151) 
Majority of the patients, in both the cases as well as the control groups were males. (p 
value- 0.950) Since our hospital caters to population all over India, we had a heterogeneous 
population with majority of our cases and controls coming from the eastern part of India. 
While for the northern and the southern parts, the cases were almost equally distributed. (p 
value-0.511). 72.7 % of all the smokers had TCC bladder. It was interesting to note that 66.6 
% of the cases were aware of the fact that smoking causes TCC bladder but they still 
continue to smoke 
36.5 % of our cases and 17.3 % of our controls were exposed to various forms of toxins due 
to their occupation. But this difference was not statistically significant. 
Table 5 
The clinicopathological characteristics of Transitional cell carcinoma (n=52) patients 
Variable  Mean ± SD or n(%) 
Age(yrs) 56.2 ± 10.6 
Tumor stage Non-muscle invasive (pTa- pT1) 40(76.9) 
Muscle invasive(pT2-T4) 12(23.7) 
Pathological grading Low grade 11(21.1) 
High grade 41(78.8) 
Tumor number Single 32(61.5) 
Multiple 20(38.5) 
 
As shown in the table 5, the mean age of the cancer patients were 56.2 ± 10.6 years. 
Majority (76.9%) of the patients were having non-muscle invasive disease. The patients who 
had muscle invasive disease ultimately underwent radical cystectomy and were cured of the 
disease. 
In 78.8 % of tumour was of the higher grade. 72.7 % of all the smokers had TCC bladder and 
amongst them 75 % had the disease of higher grade which is much more aggressive. 61.5 % 
of the patients had single tumour in the bladder 
 
Genotyping 
Table 6 
The Genotype distribution of the GSTP1 polymorphism between the cases and controls 
Genotype GSTP1 Cases(52) Controls(46) P value 
ile/ile (AA) 33(63.4%) 31(67.4%)  
.202 Ile/val (AG) 18(34.6%) 11(23.9%) 
val/val (GG) 1(1.9%) 4(8.7%) 
 
The GSTP1 genotype was in Hardy-Weinberg equilibrium for the controls (X2 = 0.68) 
The frequency of both the homozygous wild type and homozygous Polymorphic allele were 
more in the Control group. We noticed that the predominant allele in both the cases and 
controls were the wild type i.e. isoleucine- isoleucine i.e. 63.4% and 67.4% respectively 
It was interesting to note that the heterozygous polymorphic allele (AG) was seen more 
frequently in the cancer patient group as compared to the control group i.e. (34.6% vs 
23.9%). 
However, there was no statistically significant difference seen in the allele distribution 
among cases and control (p value- .202), suggesting the lack of association of the 
homozygous or heterozygous valine allele with TCC bladder 
Subset analysis of the genotype frequencies- For geographic distribution i.e. North 
Indians, East Indians and South Indians 
Table 7 
The distribution of GSTP1 genotype according to the geographic origin  
7a 
 
North-Indians 
 Ile/ile(AA)(14) Ile/val(AG)(4) val/val(GG)(1) P value 
Cases 8 2 0 1.00 
Controls 6 2 1 
 
 
7b 
 
East Indians 
 Ile/ile(AA)(34) Ile/val(AG)(20) val/val(GG)(1) P value 
Cases 19 12 0 .888 
Controls 15 8 1 
7c 
 
South 
Indians(24) 
 Ile/ile(AA) (13) Ile/val(AG)(8) val/val(GG) (3) P value 
Cases 6 5 0 .223 
Controls 7 3 3 
 
A subset analysis of the genotype frequencies and their association with TCC bladder was 
performed among the patients stratified based on the geographic origin i.e. from North 
India, East India or from South India, as shown in the table 7 
Although we observed that majority of our patients were from North-East part of India, 
there was no significant association with any of the genotypes in various regions with TCC 
bladder. 
Table 8 
 Subset analysis of the genotype frequencies- For Smoking 
Subset analysis of the genotype frequencies- For Smoking 
 Genotype frequency  
Ile/ile (AA) Ile/val(AG) Val/val (GG) p-value 
 
Smokers 
Subjects n-30 n-13 n-1  
0.38 Cases 22 10 0 
Controls 8 3 1 
 
We did a subset analysis to look for genotype frequency among smokers as shown in Table 
8. Majority (73.3%) of the smokers with TCC had the wild type allele, a few (31.2%) had 
ile/val heterozygous genotype, and none of them had homozygous polymorphic valine 
allele. Even among the control group, majority (66.6%) of the smokers had TCC with wild 
type homozygous allele and 25% had ile/val heterozygous allele and 0.08 % had 
homozygous polymorphic allele.  
But there was no statistically significant difference among the cases and controls, suggesting 
that the Polymorphic GSTP1 does not add to the susceptibility of TCC even among smokers. 
 
 
 
 
 
 
 
 
 
 
Summary of results: 
Both our groups, the cases as well as controls were well matched for various demographic 
variables and there was no confounding factor seen.  Most of our patients were from the 
eastern part of India and South India. Majority of the patients were males, probably due to 
the fact that in India males are more exposed to smoking and also they have higher chances 
of occupational exposure. Though majority of our patients were aware of the fact that 
smoking predisposes to cancer, the incidence of smoking was quite high in both the groups. 
High grade, non muscle invasive tumours were seen more frequently, may be due to higher 
numbers of smokers in our study group.  
The GSTP1 genotype in our study group was in concordance with the Hardy Weinberg 
equilibrium. We noticed that there was no association of TCC bladder and heterozygous or 
homozygous polymorphic valine allele in our cohort studied. The subset analysis of the 
population dividing them into 3 different regions of India as well as according to the 
smoking habits also did not show any statistically significant association with the GSTP1 
polymorphism. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Discussion 
 
 
 
 
 
 
 
 
GSTP1 plays an important role in protecting cells from the cytotoxic and carcinogenic 
agents. It forms the thioester bond between the sulphur atom of GSH and the substrate and 
then catalyzes the conjugation of reduced glutathione (GSH) with the compounds that 
contain an electrophilic. It also detoxifies the organic hyper-oxides by the reduction 
reaction.(64) 
Altered GSTP1 activity and expression have been reported in many tumors and it is largely 
due to GSTP1 DNA hypermethylation at the CpG island in the promoter-5’ region.(49) The 
GSTP1 313 A/G polymorphism at the nucleotide level leads to an amino acid variation of 
isoleucine/valine at codon 105 in the protein. The valine amino acid results in decreased 
enzyme activity and greater propensity to development of carcinoma.   
Polymorphism at the GSTP1 locus is of particular importance since this gene is universally 
present in many cell types including types including lung (Ryberg et al., 1997), (65) colon 
(Welfare et al., 1999)(66), and breast cancer (Helzlsouer et al., 1999) (67) 
Since this protein is often over-expressed in tumour cells, it can make them resistant to anti 
cancer treatment.  
Role of genetic polymorphism in bladder cancer is being evaluated in various studies done 
at different centers with heterogeneous ethnic background. Thus, we conducted a case-
control polymorphic study to assess the role of Glutathione S transferase GSTP1 
polymorphism A/G in urothelial cancers of the bladder in our patient cohort. 
 
The frequencies of the A/A, A/G, and G/G genotypes in our case i.e. TCC group were 63.4%, 34.6% and 1.9% 
while the frequency in control group were 67.4%, 23.9%, and 8.7%, respectively. The genotypes were in Hardy 
Weinberg equilibrium among both the cases and the controls. 
Our demographic variables were similar to other studies done concerning TCC bladder and 
GSTP1 polymorphism. The genotype frequency of our control population was similar to 
what was seen by other Indian studies by Vettriselvi et al., 2006(68) and Pandith et al(63) 
i.e. AA 67.4%, AG 23.9%, GG 8.7% and AA 58.4%, AG 38.4%, GG 3.1% and AA 76%, AG 22% 
and GG 2%for ile/ile (AA), ile/val (AG) and val/val (GG), respectively.  
We observed no association of GSTP1 A/G or G/G polymorphism with Urothelial cancers of the 
bladder among both the groups in our study (p- .202). However it was interesting to note that the 
frequency of heterozygous genotype was seen more frequent among cases. This heterozygous state 
can lead to in decreased enzyme activity and greater propensity to development of 
carcinoma.   
Similar lack of association was also seen in another study done on Kashmiri population India 
by Pandith et al in 2013(63) Our study was also in accordance to a German Study by 
Steinhoff et al (62) and a Japanese study by Katoh et al (61) (Table -9) who observed no 
association for GSTP1 A/G or G/G genotype with susceptibility to bladder cancer. 
 
 
 
 
 
 
Table 9: Studies showing No association between GSTP1 polymorphism and TCC bladder 
 Present study 2014 Pandith et al 2013 Katoh et al 1999 Steinhoff et al 2000 
Genotype Cases% 
(n-52) 
Controls% 
(n-46) 
Cases% 
(n-180) 
Controls% 
(n-210) 
Cases% 
(n-106) 
Controls% 
(n-122) 
Cases% 
(n-135) 
Controls% 
(n-127) 
ile/ile (AA) 63.4 67.4 71.6 76 70.8 76.2 50 55 
Ile/val(AG) 34.6 23.9 25.0 22 24.5 19.7 44 36 
Val/val(GG) 1.9 8.7 3.4 2.0 4.7 4.3 7 9 
 
 
 
 
Table 10: Studies showing a Positive association of GSTP1 polymorphism and TCC bladder 
 Safarinejad et al 2011 Srivastava et al 2005 Cao et al 2005 Harries et al 1997 
Genotype Cases% 
(n-166) 
Controls% 
(n-332) 
Cases% 
(n-106) 
Controls% 
(n-370) 
Cases% 
(n-145) 
Controls% 
(n-170) 
Cases% 
(n-71) 
Controls% 
(n-155) 
ile/ile(AA) 32.5 51.8 31.1 51.6 53.1 54.7 35.2 51 
Ile/val(AG) 53.0 45.8 54.7% 44.9 45.5 38.8 45.1 42.5 
Val/val(GG) 14.5 2.4 14.2% 3.5 1.4 6.5 19.7 6.5 
 
 
Our study was in contrary to many other studies as shown in the table 10. Srivastava et al in 
2005 (58), Safarinejad et al in 2011(34), Cao et al in 2005(69) and Harries et al in 1997 (70) 
showed a significant association of the polymorphic valine allele with the increased risk for 
the urothelial cancer of the bladder. All these studies had much higher number of cases as 
well as controls, as compared to our study. 
Smoking is a well known risk factor for TCC of the bladder(69). Smokers in our study had a 
higher grade of cancer (71). We performed a subset analysis comparing all the smokers with 
TCC bladder and the smokers seen in the control group. Majority of the smokers with TCC 
had the wild type allele, a few had ile/val heterozygous genotype, none of them had  
homozygous polymorphic  valine allele  Table- 8, We noticed no statistically significant 
difference among the cases and controls, suggesting that the Polymorphic GSTP1 does not 
add to the susceptibility of TCC even among smokers.  
We also attempted to correlate clinical stage and/or pathological grade with GSTs 
genotypes for the risk of bladder cancer, but no association was observed. Our findings 
concur with previous studies that also showed non-significant association of GSTP1 
genotypes with grade/or stage of the disease 
Our hospital caters to a wide variety of populations from all parts of India. We noticed that 
the cases seen at our centre were derived from predominantly East India and the South 
India, as shown in the table 7. When we performed the subset analysis of the cases 
according to the regional variations, we found no association of GSTP1 polymorphism with 
increased or decreased risk of TCC of the bladder. 
It is believed that Indian population is genetically heterogeneous, consisting of continuum of 
the genetic spectrum bridging Central European (CEU) and Chinese (CHB), the two distinct 
HapMap populations (72). The north Indians, the North east and the South Indians are 
believed to have different genetic lineage, though significant admixture has happened over 
several thousand years. This heterogeneity can explain variability in the genotype 
frequencies among different subpopulations in India.  
 
The lack of association noticed in our noticed can be attributed to one of the following. 
1. Small sample size 
2. Complex interaction between polymorphisms of other glutathione enzymes 
[possibilities of epistasis] e.g. GSTM1 and GSTT1 genotypes as observed by 
Safarinejad et al(34) and Srivastava et al(58) with GSTP1 
This needs further exploration by studying a larger sample size as well as looking in to the 
polymorphisms of other GST enzymes. The elucidation of complex interactions among 
different enzymes of glutathione enzymes in the xenobiotic pathways can be attempted by 
performing epitasis analysis once all the polymorphism frequencies are studied. 
 
 
 
 
 
 
  
 
Conclusion 
 
 
 
 
 
 
 
 
 
Although lack of association between GSTP1313 G/G polymorphism and UC of bladder was 
seen in our study, it might be due to a small sample size or the effect of complex interaction 
between polymorphisms of other glutathione enzymes. It is also possible that the 
polymorphism is not associated with UC of bladder in our population. For further 
confirmation, large scale population-based studies are required. 
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Patient data 
Department of Medical Genetics  
Name  
CMCH No.  
Date of birth  
Date of sample  
DNA number Pedigree no.(if applicable) 
Name and address of the submitting person  
Diagnostic criteria 1. 
2. 
Diagnosis   
Purpose of investigation  Diagnostic 
Research  
 
 
 
Department of Urology 
Name 
Age/sex 
HNUM 
Residence: North Indian, North- East Indian or South Indian 
Education level 
Smoker 
No of years smoking 
No of cigarettes smoking per day 
Passive smoking 
Awareness that smoking causes cancer 
History of cancers in the family 
Occupational exposure 
Months/ years of occupational exposure 
Other risk factors present if any 
Reasons for cystoscopy in control group 
Cystoscopy:  Tumours 
1. Number 
2. Site  
3. Papillary or sessile 
Histology: Non-muscle invasive disease/ Muscle invasive disease 
Grade of the tumour-: Low/High  
Genotype:  Isoleucine/isoleucine (AA), isoleucine/valine (AG) or valine/valine (GG) 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 

 
